Skip to content
Main Navigation
About us
Company profile
Our values
Our strategy
Board of directors
Senior Management
Our history
Innovation and research
Technology platform
Therapeutic areas
Scientific papers and presentations
Pipeline
Partnering
Our approach
Our partnerships
Investors
Financial reports and presentations
Share information
Analyst coverage
Major shareholders
Tax Value per Share
Financial calendar
Corporate governance
Corporate governance statements
ESG
Dividend policy
Annual general meeting
Articles of association
Safe harbour statement
Whistleblower policy
Risk management
Investor relations policy
Email alerting service
Media
News and announcements
Image library
Glossary
Careers
Life at Nykode
Meet us
Open positions
ESG
Search
Media
News and Announcements
Newest first
Oldest first
Announcements
News
Search
Reset
09/11/2017
QUARTERLY REPORT – 2017 Q3
31/08/2017
QUARTERLY REPORT – 2017 Q2
03/08/2017
VACCIBODY ANNOUNCES FILING OF A CLINICAL TRIAL APPLICATION (CTA) FOR CANCER NEOANTIGEN VACCINE VB10.NEO WITH GERMAN REGULATORY AUTHORITY (PEI) AND APPOINTMENT OF MADS BUHL AXELSEN AS CHIEF MEDICAL OFFICER (CMO)
21/06/2017
Vaccibody announces positive results from the 12-month analysis of the phase I part of the clinical trial VB C-01 in patients with high-grade cervical dysplasia
23/03/2017
Vaccibody AS announces vaccination of first patient in its phase IIa study with VB10.16 immunotherapy for patients with HPV16 induced high grade lesions of the cervix
Pages:
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
Load more
Sorry, nothing found in this query
Privacy statement
Cookie policy
Disclaimer
